Table of contents:
- Reduksin Met
- Release form and composition
- Pharmacological properties
- Indications for use
- Reduksin Met, instructions for use: method and dosage
- Side effects
- special instructions
- Application during pregnancy and lactation
- Pediatric use
- With impaired renal function
- For violations of liver function
- Use in the elderly
- Drug interactions
- Terms and conditions of storage
- Terms of dispensing from pharmacies
- Reviews about Reduksin Met
- Price for Reduxin Met in pharmacies
- Reduxin Met: prices in online pharmacies
Video: Reduxin Met - Instructions For Use, Reviews, Price, Analogues
Reduxin Met: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Reduxin Met
ATX code: A08A, A10BA02
Active ingredient: metformin (Metformin) + sibutramine (Sibutramine) + microcrystalline cellulose (MCC) [microcrystalline cellulose (MCC)]
Manufacturer: LLC "Ozon" (Russia)
Description and photo update: 2019-10-12
Prices in pharmacies: from 1988 rubles.
Reduxin Met is a combined preparation containing two medicines in one package: capsules for the treatment of obesity and pills that have a hypoglycemic effect.
Release form and composition
The drug is produced in the form of a kit - tablets 850 mg (metformin) and capsules 10 mg + 158.5 mg [sibutramine + microcrystalline cellulose (MCC)] or tablets 850 mg (metformin) and capsules 15 mg + 153.5 mg (sibutramine + MCC): tablets - biconvex, oval, almost white or white, with a risk on one side; capsules - size No. 2, blue (10 mg + 158.5 mg) or blue (15 mg + 153.5 mg) color, contents - white or white powder with a yellow tint (10, 20, 25, 30 or 60 tablets in a blister and 7, 10, 14 or 15 capsules in a blister, in a cardboard box of 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20 or 22 blisters with tablets and 1-11 contour packs with capsules; 10, 20, 25, 30, 40, 50, 60, 100 or 120 tablets in a polymer can and 7, 10, 14, 15, 28, 30, 60, 90, 120, 150,160 or 180 capsules in a polymer container; in a cardboard box 1 jar of tablets and 1 container of capsules. Each pack also contains instructions for the use of Reduxin Met).
1 tablet contains:
- active substance: metformin hydrochloride - 850 mg;
- additional components: croscarmellose sodium, MCC, povidone K17 (polyvinylpyrrolidone), magnesium stearate, purified water.
1 capsule contains:
- active ingredients: sibutramine hydrochloride monohydrate - 10 or 15 mg and MCC - 158.5 or 153.5 mg, respectively;
- additional component: calcium stearate;
- capsule shell: gelatin, titanium dioxide, patented blue dye (capsules 15 mg), dyes azorubin and brilliant blue (10 mg capsules).
Reduksin Met in one package contains 2 separate medicinal products: the hypoglycemic agent metformin (tablets) and the agent for the treatment of obesity, which includes sibutramine and MCC (capsules). The combined use of these active substances increases their therapeutic efficiency in patients with overweight and type 2 diabetes mellitus.
Metformin is an oral hypoglycemic agent from the biguanide group. It leads to a decrease in hyperglycemia without causing hypoglycemia, does not stimulate insulin production, and does not demonstrate a hypoglycemic effect in healthy individuals. Promotes an increase in the sensitivity of peripheral receptors to insulin and accelerates the utilization of glucose by cells. It slows down the course of gluconeogenesis in the liver, inhibits the absorption of carbohydrates in the intestine by acting on the glycogen synthase enzyme, and activates the production of glycogen. Metformin provides an increase in the transport capacity of all types of membrane glucose transport proteins, has a beneficial effect on lipid metabolism, reducing the level of total cholesterol (Xc), low density lipoprotein (LDL) and triglycerides (TG).
Body weight during metformin therapy either remains stable or decreases to a moderate extent.
Sibutramine belongs to prodrugs and realizes its action in vivo through metabolites (primary and secondary amines) that suppress the reuptake of monoamines (norepinephrine, serotonin and dopamine). An increase in the content of neurotransmitters in synapses increases the activity of central adrenergic and 5-HT-serotonin receptors, which leads to an increase in the feeling of satiety and decreases the need for food, and also increases thermal production. Sibutramine has an effect on brown adipose tissue, indirectly activating β 3-adrenergic receptors. The decrease in body weight occurs simultaneously with an increase in the serum level of high density lipoproteins (HDL) in the blood and a decrease in the amount of total cholesterol, LDL, TG and uric acid. The original active ingredient and its metabolites do not affect the release of monoamines, do not suppress the enzyme monoamine oxidase (MAO), and do not possess affinity for a significant number of neurotransmitter receptors, such as dopamine (D 1, D 2), adrenergic receptors (β 1, β 2, β 3, α 1, α 2), serotonin (5-HT 1, 5-HT 1A, 5-HT 1B, 5-HT 2C), histamine (H1), muscarinic, benzodiazepine and glutamate NMDA receptors.
Microcrystalline cellulose (MCC)
MCC belongs to enterosorbents, demonstrates sorption properties and non-specific detoxification effect. Binds and excretes from the body a variety of microbes, their metabolic products, allergens, xenobiotics, toxic substances of an endogenous or exogenous nature, as well as an excess of certain metabolites and metabolic products that provoke the development of endogenous toxicosis.
After oral use, the active substance is well absorbed from the gastrointestinal tract (GIT), if taken simultaneously with food, its absorption decreases and slows down. The absolute bioavailability of metformin is 50-60%, the maximum concentration (C max) in plasma is approximately 2 μg / ml or 15 μmol and is noted 2.5 hours after administration.
Metformin is rapidly distributed in the tissues of the body, its connection with plasma proteins is extremely insignificant. Biotransformation is very weak. It is excreted by the kidneys; in healthy individuals, the clearance of metformin is 400 ml / min, which is 4 times higher than the clearance of creatinine (CC), this fact confirms the active tubular secretion. The half-life (T 1/2) averages 6.5 hours.
After oral administration, it is rapidly and to a high degree, not less than 77%, absorbed from the gastrointestinal tract. Undergoes metabolism during the initial passage through the liver with the participation of the isoenzyme CYP3A4 with the formation of 2 active metabolites - monodesmethylsibutramine (M1) and didesmethylsibutramine (M2). When taking sibutramine in a single dose of 15 mg, C max M1 in the blood is 4 ng / ml (3.2-4.8 ng / ml), and C max M2 is 6.4 ng / ml (5.6-7.2 ng / ml). After oral administration, C max of sibutramine is fixed after 1.2 hours, C max of active metabolites - after 3-4 hours. Simultaneous administration of the drug with food reduces C max of metabolites by 30% and increases the time to reach it (T Cmax) for 3 hours without changing the area under the concentration-time curve (AUC).
Sibutramine is intensively distributed throughout tissues, binds to proteins by 97%, and its metabolites M1 and M2 by 94%. The equilibrium concentration (C ss) of the latter in the blood is reached within 4 days after the start of treatment and is approximately 2 times higher than the plasma concentration after taking a single dose.
Active metabolites are biotransformed by hydroxylation and conjugation to form inactive metabolites, which are excreted mainly by the kidneys. T1 / 2 of sibutramine is 1.1 hours, M1 - 14 hours, M2 - 16 hours.
According to the currently available limited data, clinically significant differences in the pharmacokinetics of sibutramine in men and women were not found.
Indications for use
Reduxin Met is recommended for use for weight loss in the following diseases / conditions:
- alimentary obesity with a body mass index (BMI) of 27 kg / m² or more against the background of type 2 diabetes mellitus and dyslipidemia;
- alimentary obesity with a BMI above 30 kg / m² in the presence of prediabetes and in the presence of additional risk factors for the development of type 2 diabetes mellitus, in cases where lifestyle changes did not allow achieving adequate glycemic control.
- cardiovascular diseases (current or in history): tachycardia, arrhythmia; ischemic heart disease (CHD) - angina pectoris, myocardial infarction (MI); chronic heart failure (CHF) in the stage of decompensation (since the threat of hypoxia and renal failure increases); cerebrovascular diseases - transient disorders of cerebral circulation, stroke; occlusive lesions of peripheral arteries;
- uncontrolled arterial hypertension - blood pressure (BP) above 145/90 mm Hg. Art.;
- clinically pronounced manifestations of diseases in acute and chronic form, which can provoke the development of tissue hypoxia, such as acute heart failure, respiratory failure, acute myocardial infarction, CHF with unstable hemodynamic parameters;
- diabetic precoma, diabetic ketoacidosis, diabetic coma;
- severe functional disorders of the kidneys (CC below 45 ml / min);
- acute conditions, against the background of which the threat of kidney dysfunction is aggravated: dehydration (with vomiting and diarrhea), severe infectious lesions, shock;
- liver dysfunction;
- chronic alcoholism, acute ethanol intoxication;
- benign prostatic hyperplasia;
- angle-closure glaucoma;
- trauma and major surgery (if insulin therapy is indicated);
- Tourette's syndrome (generalized tics);
- mental illness;
- lactic acidosis (including history);
- identified drug or pharmacological dependence;
- existing organic causes of obesity (including hypothyroidism);
- bulimia nervosa, anorexia nervosa, and other serious eating disorders;
- a period of less than 48 hours before and within 48 hours after the implementation of radioisotope or X-ray studies using an iodine-containing contrast agent (against the background of insufficient renal function in persons with diabetes mellitus during treatment with metformin, these studies can cause lactic acidosis);
- age under 18 and over 65;
- pregnancy and lactation;
- adherence to a hypocaloric diet (below 1000 kcal per day);
- combination therapy with MAO inhibitors (dexfenfluramine, phentermine, ethylamphetamine, fenfluramine, ephedrine) or their use for 2 weeks before and 2 weeks after the end of sibutramine; with other drugs that affect the central nervous system (CNS), suppressing serotonin reuptake (antidepressants), antipsychotics, hypnotics containing tryptophan, and other centrally acting drugs for reducing body weight or treating mental disorders;
- hypersensitivity to any of the components of the combined preparation.
Relative (Reduxin Met must be taken with caution):
- diseases of the coronary arteries (including indications in anamnesis), with the exception of coronary artery disease;
- chronic circulatory failure;
- glaucoma (except for the closed-angle form);
- arterial hypertension (controlled and in history);
- neurological disorders, including mental retardation and seizures (including history);
- history of verbal and motor tics;
- mild to moderate renal impairment; renal failure (CC 45-59 ml / min);
- predisposition to bleeding disorders and bleeding;
- concomitant treatment with drugs that affect platelet function or hemostasis (sibutramine increases the risk of bleeding);
- age over 60 years, in the case of heavy physical work, which is fraught with an aggravation of the risk of developing lactic acidosis.
Reduksin Met, instructions for use: method and dosage
Reduxin Met is taken orally.
Metformin tablets and sibutramine capsules should be taken at the same time, without breaking or chewing, with one glass of water, with food in the morning. Drug therapy must be carried out in conjunction with exercise and an appropriate diet, under the supervision of a physician with practical experience in the treatment of obesity.
The recommended initial dose of Reduxin Met is 1 tablet of metformin at a dose of 850 mg, and 1 capsule containing sibutramine at a dose of 10 mg.
It is required to control the dynamics of changes in blood glucose levels and the dynamics of decrease in body weight. If, after 1–2 weeks after the start of the course, it is not possible to achieve the optimal blood glucose level, the daily dose of metformin should be increased to 1700 mg (2 tablets). As a rule, the maintenance dose of metformin is 1700 mg, the maximum daily dose is 2550 mg (3 tablets). To improve gastrointestinal tolerance, the daily dose of metformin can be divided into 2 doses - 1 tablet in the morning and 1 in the evening. In the case when, within 4 weeks from the beginning of the course, there is no decrease in body weight by 2 kg, the dose of sibutramine should be increased to 15 mg per day.
If the response to therapy is not good enough, that is, within 3 months of the course, it is not possible to reduce body weight by 5% of the initial indicator, then you should not continue taking Reduxin Met. It is also inappropriate to continue therapy if, in the process of further treatment, after the previously achieved decrease in body weight, its increase by 3 kg or more is again recorded.
When treating prediabetes, it is recommended to take metformin at a dose of 850-1700 mg and sibutramine at a dose of 10-15 mg per day. If it is necessary to increase the daily dose of metformin to 1700 mg, the second tablet should be taken in the evening. It is required to regularly exercise glycemic control in order to assess the need for further use of the drug and change the dose of metformin.
The duration of therapy with Reduxin Met against the background of type 2 diabetes mellitus and prediabetes should not be more than 1 year, since there is no data on its efficacy and safety regarding a longer period of sibutramine use. In the future, it is recommended to take metformin as monotherapy.
- nervous system: often - taste disturbance;
- digestive system: very often - lack of appetite, abdominal pain, nausea, diarrhea, vomiting (these effects occur in most cases at the beginning of treatment and are mostly spontaneous); extremely rarely - violations of liver function indicators, hepatitis (after the abolition of Reduxin Met, these phenomena are completely removed);
- metabolism: extremely rare - lactic acidosis; in the case of long-term use - a decrease in the absorption of vitamin B 12; in the presence of megaloblastic anemia, a decrease in the level of this vitamin must be taken into account;
- skin: extremely rarely - skin reactions in the form of itching, rash, erythema.
- cardiovascular system (CVS): often - palpitations, tachycardia, vasodilation; increase in blood pressure - moderate rise at rest by 1–3 mm Hg. Art. and an increase in heart rate by 3–7 beats / min; in some cases - a pronounced increase in blood pressure and heart rate (HR), as a rule, clinically significant changes in pulse and blood pressure are recorded in the first 4–8 weeks of the course;
- nervous system: very often - dry mouth, insomnia; often - change in taste, anxiety, dizziness, headache, paresthesia;
- skin: often - increased sweating;
- digestive system: very often - lack of appetite, constipation; often - nausea, exacerbation of hemorrhoids; in the first days of therapy, with a tendency to constipation, it is necessary to control the evacuation function of the intestine; with the development of constipation, the capsules are stopped and laxatives are used.
During treatment with sibutramine, the following phenomena were recorded in isolated cases: thirst, a paradoxical increase in appetite, dysmenorrhea, edema, itching of the skin, abdominal pain, back pain, rhinitis, flu-like syndrome, emotional lability, drowsiness, nervousness, anxiety, irritability, depression, a temporary increase in the activity of hepatic enzymes, bleeding, Shenlein-Henoch purpura, acute interstitial nephritis, thrombocytopenia, convulsions.
In the process of post-marketing studies, additional undesirable effects of sibutramine were also noted:
- nervous system: convulsions, short-term memory impairment;
- CCC: atrial fibrillation;
- mental disorders: psychosis, states of suicidal thinking, mania and suicide; with the development of such conditions, therapy is canceled;
- allergic reactions: hypersensitivity reactions - from urticaria and mild skin rashes to Quincke's edema and anaphylaxis;
- organ of vision: blurred vision;
- skin: alopecia;
- digestive system: vomiting, diarrhea;
- reproductive system: menstrual irregularities, ejaculation / orgasm disorders, impotence, uterine bleeding;
- urinary system: urinary retention.
When using metformin at a dose of 85 g (42.5 times higher than the maximum daily dose), hypoglycemia was not observed, but the development of lactic acidosis was noted. The appearance of this complication, therefore, is possible with a significant overdose of metformin or the presence of associated risk factors. With the development of signs of lactic acidosis, therapy with Reduxin Met should be urgently canceled. After an emergency hospitalization, the lactate level should be determined to clarify the diagnosis. The most effective method for the elimination of lactate and metformin from the body is hemodialysis. Symptomatic treatment is also indicated.
According to the available extremely limited information about an overdose of sibutramine, its most common symptoms may be dizziness, headache, increased blood pressure, tachycardia. In case of suspicion of intoxication, an urgent need to consult a doctor. There are no specific antidotes or special therapy. It is recommended to carry out general measures, such as monitoring the state of the CVS, ensuring free breathing. If necessary, supportive and symptomatic treatment is prescribed. Timely intake of activated charcoal and gastric lavage can reduce the intake of an excessive dose of sibutramine. If there is an increase in blood pressure and the development of tachycardia, β-blockers may be prescribed. Hemodialysis and forced diuresis are ineffective.
In case of an overdose, taking Reduxin Met should be stopped immediately.
As a result of the accumulation of metformin, in rare cases, such a serious complication as lactic acidosis can occur, which is characterized by high mortality in the absence of urgent therapy. Most often, lactic acidosis was observed in individuals with diabetes mellitus and severe renal failure. Associated risk factors for the development of this complication are prolonged fasting, ketosis, decompensated diabetes mellitus, liver failure, alcoholism, and any condition leading to severe hypoxia.
Consideration should be given to the threat of lactic acidosis with the development of such nonspecific signs as muscle cramps with dyspeptic symptoms, severe asthenia and abdominal pain. Lactic acidosis is characterized by acidotic dyspnea, abdominal pain, and hypothermia followed by coma. Diagnostic laboratory indicators of this disease include a decrease in blood pH (below 7.25), a plasma lactate content of more than 5 mmol / l, an increase in the anion gap and the lactate / pyruvate ratio. In case of suspicion of metabolic acidosis, you must stop taking the drug and immediately consult a doctor.
When carrying out a planned surgical intervention, the use of Reduxin Met should be suspended 48 hours before the operation and resumed no earlier than 48 hours after its completion, provided that the kidneys function normally.
Due to the fact that metformin is excreted by the kidneys, before the start of the course of treatment and regularly during its course, it is required to determine the CC value: in persons with normal renal function - at least once a year, in elderly patients, as well as in patients with a CC indicator reaching the lower border of the norm - 2-4 times a year.
With the combined use of Reduxin Met with non-steroidal anti-inflammatory drugs (NSAIDs), antihypertensive drugs, diuretics, special care must be taken because of possible renal dysfunction.
To control diabetes mellitus, regular routine laboratory tests are recommended during treatment.
Patients are required to continue on a diet with even carbohydrate intake throughout the day. If you are overweight, you should then follow a hypocaloric diet (but not less than 1000 kcal per day).
An essential component of treatment is the creation of the prerequisites for a persistent change in lifestyle and eating behavior necessary to maintain, after discontinuation of drug therapy, the weight loss achieved during the period of its implementation.
Against the background of treatment with Reduxin Met, it is necessary in the first 3 months of the course to monitor blood pressure and heart rate every 2 weeks, and then every month. In persons with arterial hypertension, in whom, during the implementation of antihypertensive therapy, blood pressure ≥ 145/90 mm. rt. Art., this control should be carried out especially carefully and at shorter intervals. If, upon repeated measurement, blood pressure was twice above 145/90 mm Hg. Art., taking the drug must be suspended.
With extreme caution, Reduxin Met should be combined with drugs that increase the QT interval, which include blockers of histamine H 1 receptors (terfenadine, astemizole), antiarrhythmic drugs (flecainide, amiodarone, propafenone, quinidine, mexiletine, sotalol), a stimulant of gastrointestinal tract motility, cyzapol., tricyclic antidepressants (doxepin, amitriptyline), sertindole, pimozide. It is required to take into account that conditions such as hypomagnesemia and hypokalemia can also lead to an increase in the QT interval.
Influence on the ability to drive vehicles and complex mechanisms
The use of Reduksin Met can limit the ability to drive vehicles and control complex mechanisms. During the period of treatment, special care should be taken when engaging in activities that require increased concentration of attention and speed of reactions.
Application during pregnancy and lactation
The use of Reduxin Met during pregnancy is contraindicated, since until now there has not been a sufficient number of adequate studies regarding the safety of the effect of sibutramine on the fetus.
During therapy, patients of reproductive age are required to use contraceptives.
Taking Reduxin Met is contraindicated for lactating women.
Reduksina Met is not prescribed to patients under 18 years of age.
With impaired renal function
In the presence of renal failure, T 1/2 of metformin increases and the risk of accumulation of the substance in the body increases. The AUC value of sibutramine metabolites M1 and M2 is not affected by renal failure, with the exception of M2 in patients with end-stage renal disease receiving dialysis therapy.
In the presence of severe functional impairment of the kidneys (CC below 45 ml / min), treatment with Reduxin Met cannot be performed. With functional disorders of mild and moderate and renal failure (CC 45-59 ml / min) therapy can be carried out with caution.
For violations of liver function
After a single dose of sibutramine in patients with moderate hepatic dysfunction, the AUC value of metabolites M1 and M2 was 24% higher than in healthy volunteers.
In the presence of liver dysfunction, the use of Reduxin Met is contraindicated.
Use in the elderly
The pharmacokinetics of sibutramine in healthy elderly people (average 70 years) corresponds to that in younger people.
The drug is contraindicated in patients over 65 years of age. In patients over 60 years of age who perform heavy physical work, the risk of lactic acidosis increases during the period of therapy. Also, while taking Reduxin Met, elderly people should take special care because of the possible impairment of kidney function.
Possible pharmacological interaction of metformin with other medicinal substances / drugs, provided that they are used together:
- ethanol: the threat of lactic acidosis development increases against the background of acute alcohol intoxication, especially in the presence of liver failure, in the case of a low-calorie diet or malnutrition; during the period of therapy, it is not recommended to take ethanol-containing drinks and medicines;
- chlorpromazine (at a dose of 100 mg per day): increases blood glucose levels and decreases insulin release; when combined with antipsychotics and after their withdrawal, it is required to adjust the dose of the drug and monitor the glucose content in the blood;
- danazol: the hyperglycemic effect of this substance is recorded, as a result of this, simultaneous administration is not recommended; if such a combination is necessary, after the end of danazol intake, it is necessary to change the dose of metformin under the control of blood glucose levels;
- glucocorticosteroids (GCS) for systemic and local use: glucose tolerance decreases and the concentration of the latter increases, sometimes leading to the development of ketosis; against the background of this combined treatment and after the completion of the GCS intake, it is recommended to adjust the dose of metformin while monitoring the blood sugar level;
- loop diuretics: the risk of lactic acidosis is aggravated due to potential functional renal failure; metformin is not used with CC below 60 ml / min;
- β2-adrenergic agonists (with injection): the concentration of glucose in the blood increases as a result of stimulation of these funds; glucose control is required, insulin may be prescribed;
- inhibitors of angiotensin-converting enzyme (ACE inhibitors) and other antihypertensive drugs: the blood glucose level decreases, the dose of metformin may need to be adjusted;
- nifedipine: increases the absorption and C max of metformin;
- morphine, amiloride, procainamide, digoxin, ranitidine, quinidine, trimethoprim, quinine, vancomycin, triamterene (cationic drugs produced in the renal tubules): an increase in the C max of metformin is possible due to its competition with these substances for tubular transport;
- insulin, sulfonylurea derivatives, acarbose, salicylates: the risk of hypoglycemia is aggravated.
Possible pharmacological interaction of sibutramine with other medicinal substances / preparations, provided that they are used together:
- macrolide antibiotics, rifampicin, carbamazepine, phenytoin, dexamethasone, phenobarbital: may increase the metabolic rate of sibutramine;
- erythromycin, ketoconazole, cyclosporine (inhibitors of the CYP3A4 isoenzyme) and other inhibitors of microsomal oxidation: increase the plasma concentration of sibutramine metabolites, increase heart rate and clinically insignificantly increase the QT interval;
- oral contraceptive drugs: the effect of sibutramine on these drugs is not recorded;
- selective serotonin reuptake inhibitors (SSRIs) (drugs for the treatment of depression), dihydroergotamine and sumatriptan (drugs for the treatment of migraines), fentanyl, pentazocine, pethidine, (powerful analgesics), dextromethorphan (antitussives) in serotonin and other drugs that increase plasma levels blood: the threat of serious interaction increases, in some cases with the development of serotonin syndrome;
- decongestants, anti-cold, antitussive and antiallergic drugs that include ephedrine / pseudoephedrine (drugs that increase blood pressure and heart rate): there is not enough data on the interaction of these drugs with sibutramine, when combined, caution is required;
- ethanol: no increase in the negative effect of this substance is recorded, however, alcohol is absolutely not combined with the diets recommended for sibutramine treatment.
Reduxin Met analogs are Reduxin, Reduxin Forte.
Terms and conditions of storage
Store in a place out of the reach of children, protected from light, at a temperature not exceeding 25 ° C.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Reduksin Met
According to reviews, Reduxin Met is an effective treatment for obesity in type 2 diabetes mellitus and prediabetes. Many people say that this drug is quite serious and should only be used as directed by a qualified doctor. During the period of therapy, to achieve a decrease in body weight and adequate control of blood glucose levels, it is necessary to strictly follow all the recommendations of the attending physician. Also, patients recommend that while taking Reduxin Met, carefully monitor your health, adhere to a diet and increase physical activity.
However, there are many complaints about the development of side effects. In some cases, they indicate an insufficient effect of Reduxin Met or no improvement after its use.
Price for Reduxin Met in pharmacies
The price of Reduxin Met, a set of tablets and capsules, can be: for a package containing 30 capsules (15 mg + 153.5 mg) and 60 tablets (850 mg) - 2700–4300 rubles; for a package containing 30 capsules (10 mg + 158.5 mg) and 60 tablets (850 mg) - 2000-2300 rubles.
Reduxin Met: prices in online pharmacies
Reduxin Met table. 850 mg + capsules (10 mg + 158.5) mg tablets and capsules set of 90 pcs.
Reduxin Met table. 850 mg + caps. (15 mg + 153.5) mg tablets and capsules set of 90 pcs.
Reduksin MET capsules 10mg + 158.5mg No. 30 tablets 850mg 60 pcs.
Reduksin MET capsules 15mg + 153.5mg No. 30 tablets 850mg 60 pcs.
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!